SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 21, 2002; DOI 10.1182/blood-2002-01-0300. This Article Abstract Full Text (PDF) All Versions of this Article: 2002-01-0300v1 100/4/1399    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gorgun, G. Articles by Foss, F. Search for Related Content PubMed PubMed Citation Articles by Gorgun, G. Articles by Foss, F. Related Collections Chemokines, Cytokines, and Interleukins Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 August 2002, Vol. 100, No. 4, pp. 1399-1403 IMMUNOBIOLOGY Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox Gullu Gorgun and Francine Foss From the Department of Hematology Oncology and Experimental Therapeutics, Tufts New England Medical Center, Boston, MA.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Rexinoids binding to both the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of rexinoid receptors have demonstrated clinical activity in hematologic malignancies and have been shown to mediate genes associated with both growth and differentiation. RXR rexinoids have demonstrated efficacy in the treatment of cutaneous T-cell lymphomas, but the mechanism of action is unclear. We explored the immunomodulatory effects of RAR and RXR rexinoids in human T- and B-cell leukemia cells and demonstrated that RXR rexinoids are capable of up-regulating high-affinity interleukin-2 receptor (IL-2R) expression. Exposure to 106 to 1010 M bexarotene or Panretin for 48 hours was associated with increased expression of both the p55 and p75 subunits of the IL-2R in T-cell leukemias and p75 in B-cell leukemias. Furthermore, rexinoid exposure enhanced susceptibility of the cells to denileukin diftitox fusion toxin-targeting and -intoxicating cells expressing high-affinity IL-2R. These results suggest a rationale for combining rexinoids with IL-2R-targeted therapies in lymphoid malignancies as well as possibly in autoimmune diseases. (Blood. 2002;100:1399-1403) © 2002 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Rexinoids are ligands for transcription factors of the nuclear receptor superfamily. Two subfamilies of rexinoid receptors have been identified, retinoic acid receptor (RAR)- receptors, which function in differentiation and cell growth, and retinoid X receptor (RXR)- receptors, which regulate a family of genes with RXR receptor elements and, which, in some instances, induce apoptosis in tumor cells.1,2 All-trans-retinoic acid (ATRA) has been identified as an RAR-specific ligand,3 bexarotene (Targretin, LGD 1069; Ligand Pharmaceuticals, San Diego, CA) is a selective RXR ligand, and alitretinoin (Panretin, LGD 1057; Ligand Pharmaceuticals) has been demonstrated to bind to both RAR and RXR receptors.4 Rexinoids have been shown to have important immunomodulating effects on T cells, including augmenting interleukin-2 receptor (IL-2R) expression by activated T cells and inhibiting activation-induced cell death. Sidell and coworkers5 demonstrated that ATRA up-regulated the expression of IL-2R on human thymocytes by increasing the steady-state messenger RNA levels. Although RXR rexinoids (rexinoids) have been shown to induce apoptosis in HL60 cells and human epithelial cell lines without modulating expression of differentiation markers, it is unclear whether rexinoids (rexinoids) would similarly modulate the activation state of T cells.6-8 We examined the differential effects of both RAR and RXR rexinoids on IL-2R expression in human leukemia cells. Up-regulation of high-affinity IL-2R would enhance the susceptibility of the cells to intoxication by the IL-2 fusion toxin, denileukin diftitox (Ontak), whose mechanism of cytotoxicity is dependent on efficient binding to the high-affinity IL-2R, with subsequent receptor-mediated internalization of the toxin.9,10 We demonstrate up-regulation of the IL-2R (CD122) subunit by both RAR and RXR rexinoids in T cells, but more selective effects in B cells, with up-regulation of IL-2R (CD122) but not IL-2R (CD25) expression. In both Sezary T-leukemia cells and B cells of chronic lymphocytic leukemia (B-CLL), up-regulation of the high- affinity IL-2R was demonstrated by enhanced susceptibility to intoxication by Ontak. Our results demonstrate both a potential immunomodulatory effect of rexinoids on the activation state of T cells as well as a biomodulatory effect of these agents to sensitize leukemia cells to targeted cytotoxic therapies.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Cell culture Cutaneous T-cell lymphoma (CTCL) NCI-HUT78, HUT102, pre-B cell line NALM6, and acute lymphoblastic leukemia cell line CEM were obtained from the American Type Culture Collection (Manassas, VA). Fresh cells from patients with CTCL and B-CLL were isolated by Ficoll-Hypaque centrifugation. Cells were grown in complete medium (RPMI-1640 medium including 10% fetal bovine serum, 50 µg/mL glutathione, 50 µg/mL streptomycin, and 50 µg/mL penicillin). Chemicals Denileukin diftitiox (Ontak, DAB389IL2), alitretinoin (Panretin, LGD 1057; 9-cis retinoic acid; 3,7-dimethyl-9-[2,6,6-trimethyl-1-cyclohexen-1-yl]-2-trans-4-trans-6-cis-8-trans-nonatetraenoic acid), and bexarotene (Targretin, LGD 1069; 4-[1-(3,5,5,8,8,-pentamethyl-5,6,7,8-tetrahydro-2-napthalenyl) ethenyl] benzoic acid) were obtained from Ligand Pharmaceuticals. Flow cytometry Cells were incubated with 106 M and 108 M rexinoids (ATRA, alitretinoin, and bexarotene) in complete medium at 37°C in 5% CO2 for 48 hours and then labeled with phycoerythrin (PE)-conjugated monoclonal antihuman CD25 PE (IL-2R) and CD122 PE (IL-2R) (Becton Dickinson, CA) antibodies, fixed, and analyzed using FACScan (Becton Dickinson, Beckman Instruments, San Jose, CA) Laser excitation was set at 488 nm. IL-2R subunit analysis by Western immunoblot Cells (5 × 105 cells/mL) were incubated with 106 M and 108 M rexinoids for 48 hours and lysed; proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes at 100 V for 1 hour. Immunoblots were performed using antibodies to human IL-2R, IL-2R, and IL-2R (Santa Cruz Biotechnology, Santa Cruz, CA). Immunoreactive bands were detected by Western blot chemiluminescence reagents (NEN Life Science, Boston, MA) and exposed on Kodak XAR film (Rochester, NY). The protein bands were stained by Coomassie blue to demonstrate the amount of protein loaded per lane. The constitutively expressed Coomassie blue-stained protein bands were used as control. Inhibition of protein synthesis by [14C]-leucine incorporation assay Cells were seeded in 96-well flat-bottomed tissue culture plates (Costar, Cambridge, MA), 5 × 103 cells/100 µL in complete medium, and treated with106 to 1010 M rexinoids for 48 hours. Cells were exposed to106 to 1014 M denileukin diftitox for an additional 72 hours. The plates were centrifuged for 5 minutes at 170g, and the medium removed and replaced with 100 µL leucine-free medium containing 0.25 µCi [14C]-leucine (0.00925 MBq; New England Nuclear, Boston, MA). Cells were incubated at 37°C for 3 hours; then protein was precipitated by trichloroacetic acid (TCA) and harvested on glass fiber filters. Incorporation of [14C]-leucine was quantified by scintillation counting. All assays were performed in triplicate and results were reported ± SEM of triplicate assays. MTT cell cytotoxicity assay Cells were seeded in triplicate in 96-well plates in 50 µL complete media at a density of 5 × 103 cells/well. The 50-µL aliquots of rexinoids were added to each well to give a range of concentrations from 106 to 1010 M in a final volume of 100 µL. After 48 hours of incubation, 20 µL denileukin diftitox was added to each well to give various concentrations from 106 to 1014 M. Cells were incubated for an additional 72 hours. Then 20 µL MTT (3-(4,5-dimethylthazol-2-yl)-2,5-diphenyl tetrazolium bromide salt) from 5 mg/mL stock was added at the last day and incubated for 4 hours. The formazan crystals were solubilized by adding 100 µL 20% SDS in 50% dimethyl formamide (DMF; pH 4.7) and incubating at 37°C overnight. The absorbance of the formazan product was measured on an enzyme-linked immunosorbent assay (ELISA) plate reader at 570 nm.     Results Top Abstract Introduction Materials and methods Results Discussion References We and others demonstrated that the CTCL cell line HUT78, acute T-lymphoblastic leukemia cell line CEM, and the pre-B cell leukemia cell lines NALM6 and Raji express low-affinity IL-2R, consisting of the p55 (IL-2R) and p64 (IL-2R) subunits and are thereby resistant to killing by denileukin diftitox (Ontak), whereas HUT102 T-leukemia cells expresses high-affinity IL-2R (p55, p75, p64) and are efficiently intoxicated by denileukin diftitox.11 Effects of rexinoids on T- and B-leukemia cells To determine the effects of rexinoids on high-affinity IL-2R expression, we exposed T- and B-leukemia cell lines and fresh leukemia cells to bexarotene, an RXR ligand, and alitretinoin, which binds to both RXR and RAR receptors. After a 48-hour incubation, there was no inhibition of cell growth by MTT and, morphologically, no induction of apoptosis in the treated cells. Expression of IL-2R subunits after rexinoid exposure is shown in Figure 1. View larger version (39K): [in this window] [in a new window]   Figure 1. The cell surface expression of CD25 (IL-2R) and CD122 (IL-2R). CTCL cell line HUT78 (A), fresh Sezary cells from a patient with CTCL (B), and pre-B leukemia cell line NALM6 (C) were exposed to 108 M or 1010 M alitretinoin (Panretin) or bexarotene for 48 hours. The cell surface expression of IL-2R (CD25) and IL-2R (CD122) were detected by flow cytometry. The dot peak represents isotypic control, the linear peak represents CD25 and CD122 expression in untreated cells, and the filled peak represents the expression of CD25 or CD122 in rexinoid-treated cells. Both alitretinoin and bexarotene up-regulated the cell surface expression of p55 and p75 at least 4-fold in HUT78 cells and fresh CD4+CD7 Sezary cells, which lacked IL-2R expression by immunohistochemistry. Rexinoids had less effect on IL-2R expression in NALM6 and Raji cells and in human B-CLL cells, with increased the expression of p75 but not p55 (Figure 1C). Immunoblots confirmed that both alitretinoin and bexarotene increased the expression of p55 and p75 in HUT78 (Figure 2A,B) and fresh Sezary cells and only p75 in the B cells (Figure 2C). View larger version (34K): [in this window] [in a new window]   Figure 2. Intracellular expression of p55 (IL-2R) and p75 (IL-2R) proteins. Cells were treated with 106 M or 108 M alitretinoin (Panretin) or bexarotene for 48 hours. The expression of p55 and p75 was analyzed by immunoblot. (A) Lane 1, untreated HUT78 cells (control); lane 2, 1010 M rexinoid-treated cells; lane 3, 108 M rexinoid-treated cells. (B) Lane 1, untreated fresh Sezary cells; lanes 2-5, Sezary cells after exposure to 1010 M Panretin (lane 2), 108 M Panretin (lane 3), 1010 M bexarotene (lane 4), 108 M bexarotene (lane 5). (C) Expression of p75 in NALM6 (lanes 1-6) and CLL cells (lanes 7-11) after rexinoids; lanes 1, 4, and 7, untreated; lanes 2 and 8, 1010 M Panretin; lanes 3 and 9, 108 M Panretin; lanes 5 and 10, 108 M bexarotene; lanes 6 and 11, 1010 M bexarotene. The "a" represents protein band and the "b" represents the constitutively expressed on Coomassie blue-stained protein bands as a control for protein loading. RXR-selective rexinoid bexarotene (Targretin) and RAR/RXR-specific rexinoid alitretinoin (Panretin) enhanced sensitivity of T and B cells to denileukin diftitox (Ontak) To test modulation of expression of functional high-affinity IL-2R after rexinoid exposure, we exposed rexinoid-treated cells to denileukin diftitox and measured protein synthesis inhibition and cell growth. Because the mechanism of cytotoxicity of denileukin diftitiox is related to the diptheria toxin-mediated adenosine diphosphate ribosylation of elongation factor 2, inhibition of protein synthesis is indicative of efficient receptor-mediated internalization of the fusion toxin. As shown in Figure 3, panels A and B, a 50% to 70% inhibition of protein synthesis was demonstrated in HUT78 and fresh Sezary cells after exposure to alitretinoin or bexarotene, respectively. In the B cells, alitretinoin inhibited the protein synthesis by 35% compared to over 50% with bexarotene (Figure 3C). As shown, low doses of denileukin diftitox alone were associated with increased proliferation, presumably due to cytokine-mediated signaling events from binding of denileukin diftitox to intermediate- and low-affinity receptor-expressing cells.12 View larger version (21K): [in this window] [in a new window]   Figure 3. Cell susceptibility to denileukin diftitox by protein synthesis inhibition. HUT78 cells (A), Sezary cells (B), and B-CLL cells (C) were exposed to1010 M and 108 M alitretinoin (Panretin) (1) or bexarotene (2) for 48 hours. The cells were incubated with denileukin diftitox (Ontak) at various concentration for 72 hours. Inhibition of protein synthesis was measured by [14C]-leucine incorporation. All the data represent percent of counts per minute ± SEM of cells pulsed with [14C]-leucine. To confirm that inhibition of protein synthesis corresponded to increased cytotoxicity, MTT assays were performed. Bexarotene had a greater effect on enhancing cytotoxicity of denileukin diftitox than alitretinoin in both T- and B-leukemia cells, concordant to the degree of protein synthesis inhibition (Figure 4). View larger version (25K): [in this window] [in a new window]   Figure 4. Cell cytotoxicity by the combination of rexinoids and denileukin diftitox. HUT78 cells (A), Sezary cells (B), and B-CLL cells (C) were incubated with rexinoids (a, alitretinoin (Panretin); b, bexarotene) for 48 hours and exposed to denileukin diftitox (Ontak) for 72 hours at various concentrations. Cytotoxicity was measured by MTT assay. Assays were performed in triplicate and data represent counts ± SEM. The results of the cytotoxicity assays are summarized in Table 1, which demonstrates that bexarotene alone had no effect on cell number.                                View this table: [in this window] [in a new window]   Table 1. Cytotoxic effects of bexarotene and denileukin diftitox (Ontak) alone and in combination     Discussion Top Abstract Introduction Materials and methods Results Discussion References Vitamin A and its analogues influence differentiation and proliferation and may also alter immune responses. Rexinoids exert their effects by binding to the rexinoid A receptor (RAR) or the rexinoid X receptor (RXR) in the nuclei of cells, either directly or indirectly via nuclear transcription factors. As a result, rexinoids regulate the expression of a wide range of target genes.13 The effects of RAR and RXR rexinoids on IL-2R expression were determined in T and B lymphocytes, which do not express high-affinity IL-2R.11,14 IL-2R and IL-2R expression is increased after exposure of the T cells to alitretinoin or bexarotene for 48 hours, whereas only IL-2R expression was increased in B-CLL cells. These results demonstrate lineage-specific effects of rexinoids and suggest that modulation of IL-2R or IL-2R may be in part related to the state of differentiation of the cell. A number of factors have been shown to modulate expression of IL-2R subunits. The p55 subunit is induced by T-cell activation, viral gene products, protein kinase A (PKA), IL-2, IL-1, and tumor necrosis factor  (TNF-).15 Likewise, the p75 subunit, which is expressed on resting T lymphocytes, is up-regulated by activation, IL-2, and IL-4. The p64, or common  subunit, is constitutively expressed but up-regulated by IL-2 and interferon . Up-regulation of IL-2R subunits by rexinoids is most likely mediated by modulation of the binding of transcriptional elements. In the case of the RAR rexinoid, ATRA, direct binding to the PML transcription factor in acute promyelocytic leukemia cells has been shown to be the mechanism of action.16 RXR rexinoids have been shown to bind directly to RXR transcriptional elements either as homodimers or heterodimers with RAR. RXR elements have been identified in a number of genes, including the thyroid-stimulating hormone promoter and the peroxisome proliferator-activated receptor promoter.16 The differential effect of rexinoids on IL-2R expression in T and B cells may be related to interaction with other transcriptional regulators. Both RAR and RXR rexinoids inhibit activation and prevent apoptosis in B lymphocytes while inducing cell differentiation and proliferation in T lymphocytes.17 IL-2R is not expressed on resting lymphocytes but is potently induced after activation.18 IL-2R is mainly regulated at the level of transcription by induction of nuclear factor-B (NF-B) and serum response element.19 Rexinoids may induce IL-2R expression by enhancing expression of IL-2R in T lymphocytes.15 IL-2R is linked to at least 2 intracellular signaling pathways mediating nuclear proto-oncogene induction. One pathway involves tyrosine phosphorylation by janus kinase 1 (JAK1) and src-family phosphotyrosine kinases (PTKs) and leads to the induction of c-fos and c-jun through the activation of p21ras. Another pathway involves induction of c-myc and bcl-2 genes.20 Up-regulation of IL-2R, therefore, favors proliferation. Because IL-2R is constitutively expressed in lymphocytes and, via janus kinase signal transducer and activation of transcription (JAK-STAT) phosphorylation, serves as a messenger to rapidly regulate expression of target genes,21 up-regulation of IL2-R by the rexinoids enhances activation and proliferation signals even in the absence of up-regulation of IL2-R in the B cells. This may explain the effects of the RXR rexinoids alone to induce the proliferation we observed in both T- and B-leukemia cells. Up-regulation of functional high-affinity receptor by rexinoids could potentially confer susceptibility of the cells to IL-2R-targeted therapies. We demonstrate that rexinoid treatment enhanced the cytotoxicity of the IL-2R-directed fusion toxin, denileukin diftitox, in resistant T- and B-cell leukemia cells. The inhibition of protein synthesis by denileukin diftitox requires receptor-mediated internalization of the fusion toxin and intracellular processing to cleave the enzymatically active moiety of diphtheria toxin into the cytosol.22,23 The susceptibility of both normal and neoplastic cells to denileukin diftitox-induced cytotoxicity is dependent on the expression of the high-affinity IL-2R, consisting of the p55 (), p75 (), and p64 () subunits.24-26 The inhibitory concentration of 50% (IC50) of high-affinity IL-2R-expressing cells is 1012 M, whereas cells expressing intermediate-affinity receptors (p75, p64) are intoxicated at an IC50 of 1010 M.27 Cells expressing only p55 are relatively resistant (IC50 of 108 M). Expression of high-affinity IL-2R is restricted to activated T lymphocytes, activated B lymphocytes, and activated macrophages, whereas intermediate-affinity receptors are found on natural killer cells and resting T cells.28,29 In addition to up-regulation of high-affinity receptor, rexinoid exposure might have other effects on multiple signaling pathways to enhance apoptosis in the presence of the fusion toxin. Denileukin diftitox has been shown to initiate signal transduction with ligand engagement, even if receptor-mediated internalization of the fusion toxin does not occur.12 Signaling events mediated by rexinoids and IL-2R-ligand engagement may contribute to the markedly enhanced cytotoxicity observed in this study. Cell viability studies show that neither alitretinoin or bexarotene induces cell death at concentrations ranging from 106 to 108 M. Other studies have demonstrated that RXR rexinoids induce apoptosis in epithelial cell lines and in HL60 cells. RXR has been shown to be down-regulated during the transition from G0/G1 to S phase of the cell cycle, whereas RAR has been shown to facilitate apoptosis of T lymphocytes, suggesting a role for rexinoid homodimers and heterodimers in cell cycle control in lymphocytes.7,30,31 Our results demonstrate that RXR rexinoids up-regulate high-affinity IL-2R expression on human B- and T-leukemia cells. These results suggest that the clinical efficacy of denileukin diftitox might be enhanced by the addition of an RXR rexinoid, and phase I trials exploring this concept are under way. Further, bexarotene is widely used as a therapy for patients with CTCL, but its mechanism of action in this disease is unclear, because our studies demonstrate no direct cytotoxic effects on Sezary leukemia cells. The demonstration of an immunomodulatory effect of bexarotene to up-regulate high-affinity IL-2R may have consequences in the context of the generation of antitumor immunity in patients, and, likewise, it is unclear whether up-regulation of IL-2R might render the tumor cells more susceptible to fas-mediated cytotoxicity in vivo. Our results suggest that further studies of the in vivo immunomodulatory effects of bexarotene are warranted.     Footnotes Submitted January 30, 2002; accepted April 9, 2002. Prepublished online as Blood First Edition Paper, June 21, 2002; DOI 10.1182/blood-2002-01-0300. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Francine Foss, Hematology Oncology and Experimental Therapeutics, Tufts New England Medical Center, 750 Washington St, Boston, MA 02111; e-mail: ffoss{at}lifespan.org.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature. 1990;345:224-229[CrossRef][Medline] [Order article via Infotrieve]. 2. Kubota H, Chiba H, Takakuwa Y, et al. Retinoid X receptor alpha and retinoic acid receptor gamma mediate expression of genes encoding tight-junction proteins and barrier function in F9 cells during visceral endodermal differentiation. Exp Cell Res. 2001;263:163-172[CrossRef][Medline] [Order article via Infotrieve]. 3. Evans TR, Kaye SB. Retinoids: present role and future potential. Br J Cancer. 1999;80:1-8[CrossRef][Medline] [Order article via Infotrieve]. 4. Vu-Dac N, Gervois P, Torra IP, et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. J Clin Invest. 1998;102:625-632[Medline] [Order article via Infotrieve]. 5. Sidell N, Chang B, Bhatti L. Upregulation by retinoic acid of interleukin-2-receptor mRNA in human T lymphocytes. Cell Immunol. 1993;146:28-37[CrossRef][Medline] [Order article via Infotrieve]. 6. Ishaq M, Zhang YM, Natarajan V. Activation-induced down-regulation of retinoid receptor RXRalpha expression in human T lymphocytes. Role of cell cycle regulation. J Biol Chem. 1998;273:21210-21216[Abstract/Free Full Text]. 7. Szondy Z, Reichert U, Fesus L. Retinoic acids regulate apoptosis of T lymphocytes through an interplay between RAR and RXR receptors. Cell Death Differ. 1998;5:4-10[CrossRef][Medline] [Order article via Infotrieve]. 8. Ballow M, Xiang S, Greenberg SJ, Brodsky L, Allen C, Rich G. Retinoic acid-induced modulation of IL-2 mRNA production and IL-2 receptor expression on T cells. Int Arch Allergy Immunol. 1997;113:167-169[Medline] [Order article via Infotrieve]. 9. Saleh MN, LeMaistre CF, Kuzel TM, et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998;39:63-73[CrossRef][Medline] [Order article via Infotrieve]. 10. LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998;91:399-405[Abstract/Free Full Text]. 11. Bunn PA Jr, Foss FM. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem Suppl. 1996;24:12-23[Medline] [Order article via Infotrieve]. 12. Walz G, Zanker B, Brand K, et al. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Proc Natl Acad Sci U S A. 1989;86:9485-9488[Abstract/Free Full Text]. 13. Burg G, Dummer R. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL). Clin Lymphoma. 2000;1(suppl 1):S41-S44. 14. Re GG, Waters C, Poisson L, Willingham MC, Sugamura K, Frankel AE. Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res. 1996;56:2590-2595[Abstract/Free Full Text]. 15. Sidell N, Kummer U, Aframian D, Thierfelder S. Retinoid regulation of interleukin-2 receptors on human T-cells. Cell Immunol. 1997;179:116-125[CrossRef][Medline] [Order article via Infotrieve]. 16. Kurebayashi J, Tanaka K, Otsuki T, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab. 2000;85:2889-2896[Abstract/Free Full Text]. 17. Lomo J, Smeland EB, Ulven S, et al. RAR-, not RXR, ligands inhibit cell activation and prevent apoptosis in B-lymphocytes. J Cell Physiol. 1998;175:68-77[CrossRef][Medline] [Order article via Infotrieve]. 18. Leonard WJ, Depper JM, Crabtree GR, et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature. 1984;311:626-631[CrossRef][Medline] [Order article via Infotrieve]. 19. Leonard WJ, Kronke M, Peffer NJ, Depper JM, Greene WC. Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sci U S A. 1985;82:6281-6285[Abstract/Free Full Text]. 20. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol. 1993;11:245-268[CrossRef][Medline] [Order article via Infotrieve] 21. Lin JX, Leonard WJ. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev. 1997;8:313-332[CrossRef][Medline] [Order article via Infotrieve]. 22. Foss FM. DAB389IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma. 2000;1:110-116[Medline] [Order article via Infotrieve]. 23. Foss FM. DAB389IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000;1(suppl 1):S27-S31. 24. Takeshita T, Asao H, Ohtani K, et al. Cloning of the gamma chain of the human IL-2 receptor. Science. 1992;257:379-382[Abstract/Free Full Text]. 25. Tsudo M, Kozak RW, Goldman CK, Waldmann TA. Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci U S A. 1986;83:9694-9698[Abstract/Free Full Text]. 26. Shibuya H, Yoneyama M, Nakamura Y, et al. The human interleukin-2 receptor beta-chain gene: genomic organization, promoter analysis and chromosomal assignment. Nucleic Acids Res. 1990;18:3697-3703[Abstract/Free Full Text]. 27. Bacha P, Williams DP, Waters C, Williams JM, Murphy JR, Strom TB. Interleukin 2 receptor-targeted cytotoxicity: interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med. 1988;167:612-622[Abstract/Free Full Text]. 28. Sheibani K, Winberg CD, van de Velde S, Blayney DW, Rappaport H. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas: an immunohistologic study of 300 cases. Am J Pathol. 1987;127:27-37[Abstract]. 29. Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science. 1986;232:727-732[Abstract/Free Full Text]. 30. Szondy Z, Lecoeur H, Fesus L, Gougeon ML. All-trans retinoic acid inhibition of anti-CD3-induced T cell apoptosis in human immunodeficiency virus infection mostly concerns CD4 T lymphocytes and is mediated via regulation of CD95 ligand expression. J Infect Dis. 1998;178:1288-1298[CrossRef][Medline] [Order article via Infotrieve]. 31. Szondy Z, Reichert U, Bernardon JM, et al. Inhibition of activation-induced apoptosis of thymocytes by all-trans- and 9-cis-retinoic acid is mediated via retinoic acid receptor alpha. Biochem J. 1998;331:767-774. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Rasooly, G. U. Schuster, J. P. Gregg, J.-H. Xiao, R. A. S. Chandraratna, and C. B. Stephensen Retinoid X Receptor Agonists Increase Bcl2a1 Expression and Decrease Apoptosis of Naive T Lymphocytes J. Immunol., December 15, 2005; 175(12): 7916 - 7929. [Abstract] [Full Text] [PDF] R. L. Piekarz, R. W. Robey, Z. Zhan, G. Kayastha, A. Sayah, A. H. Abdeldaim, S. Torrico, and S. E. Bates T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance Blood, June 15, 2004; 103(12): 4636 - 4643. [Abstract] [Full Text] [PDF] S. Moqattash and J. D. Lutton Leukemia Cells and the Cytokine Network: Therapeutic Prospects Experimental Biology and Medicine, February 1, 2004; 229(2): 121 - 137. [Abstract] [Full Text] [PDF] A. E. Frankel, D. R. Fleming, P. D. Hall, B. L. Powell, J. H. Black, C. Leftwich, and R. Gartenhaus A Phase II Study of DT Fusion Protein Denileukin Diftitox in Patients with Fludarabine-refractory Chronic Lymphocytic Leukemia Clin. Cancer Res., September 1, 2003; 9(10): 3555 - 3561. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: 2002-01-0300v1 100/4/1399    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gorgun, G. Articles by Foss, F. Search for Related Content PubMed PubMed Citation Articles by Gorgun, G. Articles by Foss, F. Related Collections Chemokines, Cytokines, and Interleukins Social Bookmarking                   What's this?

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020